Dai Hong Phuc Vo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dai Hong Phuc Vo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ho Trong Tan Truong
Department of Urology, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam
2 shared publications - Anh Van Quoc Nguyen
Department of Urology , Hue Central Hospital , Hue , Vietnam , bvtwhue.com.vn
1 shared publication - Can Van Truong
Department of Urology , Hue Central Hospital , Hue , Vietnam , bvtwhue.com.vn
1 shared publication - Eui Hyun Jung
Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea
1 shared publication - Geehyun Song
Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea
1 shared publication - Hieu Van Le
Department of Urology , Hue Central Hospital , Hue , Vietnam , bvtwhue.com.vn
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by Elsevier in Prostate International
Bone health in prostate cancer: two clinical paradigms and the evolving role of bone-protecting agents
- 13 August 2026
- Published by Elsevier in Prostate International
Open AccessBone health in prostate cancer: two clinical paradigms and the evolving role of bone-protecting agents
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Transplantation
- Vol. 2026 (1) , 1599252
Surgical Approach to Redo Open Living Donor Nephrectomy via the Same Flank Incision: A Case Report
Living donor nephrectomy is performed with donor safety as the highest priority, and repeat donor nephrectomy through the original incision is rarely reported in transplantation literature. We present the case of a 33‐year‐old male living kidney donor and a 48‐year‐old female recipient who underwent scheduled kidney transplantation. The initial procedure was aborted before vascular ligation because the recipient developed intraoperative anaphylactic shock after anesthesia induction. Three weeks later, transplantation was reattempted using the same donor flank incision. Dense retroperitoneal adhesions were encountered, requiring posterior peritoneal dissection to safely expose the renal hilum and surrounding structures. The donor kidney was successfully harvested and transplanted without postoperative complications. This case demonstrates that repeat open donor nephrectomy via the original incision may be feasible with carefully selected patients with a cautious surgical plan and multidisciplinary perioperative management.
- 1 January 2026
- Published by Wiley in Case Reports in Transplantation
- Vol. 2026 (1) , 1599252
Open AccessSurgical Approach to Redo Open Living Donor Nephrectomy via the Same Flank Incision: A Case Report
Living donor nephrectomy is performed with donor safety as the highest priority, and repeat donor nephrectomy through the original incision is rarely reported in transplantation literature. We present the case of a 33‐year‐old male living kidney donor and a 48‐year‐old female recipient who underwent scheduled kidney transplantation. The initial procedure was aborted before vascular ligation because the recipient developed intraoperative anaphylactic shock after anesthesia induction. Three weeks later, transplantation was reattempted using the same donor flank incision. Dense retroperitoneal adhesions were encountered, requiring posterior peritoneal dissection to safely expose the renal hilum and surrounding structures. The donor kidney was successfully harvested and transplanted without postoperative complications. This case demonstrates that repeat open donor nephrectomy via the original incision may be feasible with carefully selected patients with a cautious surgical plan and multidisciplinary perioperative management.
- Open Access
- 10 April 2025
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 68 (4) , 215-227
Personalizing perioperative therapy in muscle-invasive bladder cancer: balancing oncologic benefit, toxicity, and the risk of overtreatment
Purpose: Muscle-invasive bladder cancer (MIBC) is an aggressive cancer with a high recurrence risk due to micrometastases. Standard treatment, neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy, is not suitable for all patients, with many being ineligible or experiencing recurrence, alongside significant toxicity concerns.Current Concepts: The introduction of immune checkpoint inhibitors (ICIs) into the perioperative setting —including neoadjuvant ICI use in cisplatin-ineligible patients, adjuvant ICI use in high-risk individuals, and chemoimmunotherapy in either the preoperative or postoperative period—has demonstrated promising clinical outcomes. Additionally, bladder preservation strategies are currently under investigation in select patients who exhibit favorable treatment responses, aiming to maintain quality of life without compromising oncologic outcomes. Nevertheless, challenges such as overtreatment, long-term toxicity, and immune-related adverse events remain significant, underscoring the necessity for precise patient selection.Discussion and Conclusion: To personalize perioperative management of MIBC, it is essential to develop and clinically implement robust predictive biomarkers. Assessment of molecular residual disease using circulating tumor DNA is emerging as a promising method to stratify risk, guide adjuvant treatment decisions, and monitor therapeutic response in real time. Future research should prioritize the validation of these biomarkers, refinement of patient selection criteria for bladder preservation strategies, and evaluation of novel therapeutic agents such as antibody-drug conjugates and fibroblast growth factor receptor inhibitors in the perioperative setting. Ultimately, adopting a precision oncology approach will be critical for balancing oncologic efficacy with toxicity management and achieving patient-centered outcomes.
- 10 April 2025
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 68 (4) , 215-227
Open AccessPersonalizing perioperative therapy in muscle-invasive bladder cancer: balancing oncologic benefit, toxicity, and the risk of overtreatment
Purpose: Muscle-invasive bladder cancer (MIBC) is an aggressive cancer with a high recurrence risk due to micrometastases. Standard treatment, neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy, is not suitable for all patients, with many being ineligible or experiencing recurrence, alongside significant toxicity concerns.Current Concepts: The introduction of immune checkpoint inhibitors (ICIs) into the perioperative setting —including neoadjuvant ICI use in cisplatin-ineligible patients, adjuvant ICI use in high-risk individuals, and chemoimmunotherapy in either the preoperative or postoperative period—has demonstrated promising clinical outcomes. Additionally, bladder preservation strategies are currently under investigation in select patients who exhibit favorable treatment responses, aiming to maintain quality of life without compromising oncologic outcomes. Nevertheless, challenges such as overtreatment, long-term toxicity, and immune-related adverse events remain significant, underscoring the necessity for precise patient selection.Discussion and Conclusion: To personalize perioperative management of MIBC, it is essential to develop and clinically implement robust predictive biomarkers. Assessment of molecular residual disease using circulating tumor DNA is emerging as a promising method to stratify risk, guide adjuvant treatment decisions, and monitor therapeutic response in real time. Future research should prioritize the validation of these biomarkers, refinement of patient selection criteria for bladder preservation strategies, and evaluation of novel therapeutic agents such as antibody-drug conjugates and fibroblast growth factor receptor inhibitors in the perioperative setting. Ultimately, adopting a precision oncology approach will be critical for balancing oncologic efficacy with toxicity management and achieving patient-centered outcomes.